Literature DB >> 31513453

The NEOLETEXE trial: a neoadjuvant cross-over study exploring the lack of cross resistance between aromatase inhibitors.

Nazli Bahrami1,2,3, Torill Sauer4,3,5, Siri Engebretsen2,3, Belal Aljabri1,3, Vahid Bemanian6,3, Jonas Lindstrøm7,5, Torben Lüders8,5, Vessela Kristensen8,5, Annika Lorentzen3, Marie Loeng3, Hilde Presterud Ødegård1,3, Jan Øyvind Kvaløy1,3, Ingeborg Berge Vestøl1,3, Stephanie Beate Geisler1,3, Berit Gravdehaug2,3, Joanna Majak Gundersen2,3, Jürgen Geisler1,3,5.   

Abstract

The aromatase inhibitor letrozole (Femar®/Femara®) and the aromatase inactivator exemestane (Aromasin®) differ in their biochemical effect on the aromatase enzyme. Letrozole is a competitive aromatase inhibitor while exemestane binds irreversibly to the aromatase enzyme. This pharmacological difference is of clinical interest since a lack of cross-resistance has been documented. It has been demonstrated in several clinical trials that exemestane may cause a disease regression following resistance to nonsteroidal aromatase inhibitors. The exact mechanism(s) behind this phenomenon is yet unknown. Here, we present the NEOLETEXE trial with the aim of exploring the individual mechanisms involved behind the observed lack of cross resistance. Clinical trial registration: The trial has been approved by the Regional Ethics Committee of South-East Norway (project number 2015/84).

Entities:  

Keywords:  aromatase inhibitor; breast cancer; exemestane; letrozole; neoadjuvant

Mesh：

Substances：

Year:  2019        PMID： 31513453     DOI： 10.2217/fon-2019-0258

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  4 in total

1.  Assessment of preoperative axillary nodal disease burden: breast MRI in locally advanced breast cancer before, during and after neoadjuvant endocrine therapy.

Authors:  Jürgen Geisler; Jonn Terje Geitung; Joana Reis; Joao Boavida; Hang T Tran; Marianne Lyngra; Laurens Cornelus Reitsma; Hossein Schandiz; Woldegabriel A Melles; Kjell-Inge Gjesdal
Journal:  BMC Cancer       Date:  2022-06-25       Impact factor: 4.638

2.  Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin.

Authors:  Nazli Bahrami; Shakila Jabeen; Andliena Tahiri; Torill Sauer; Hilde Presterud Ødegård; Stephanie Beate Geisler; Berit Gravdehaug; Laurens Cornelus Reitsma; Knut Selsås; Vessela Kristensen; Jürgen Geisler
Journal:  Breast Cancer Res Treat       Date:  2021-09-23       Impact factor: 4.872

3.  Accuracy of breast MRI in patients receiving neoadjuvant endocrine therapy: comprehensive imaging analysis and correlation with clinical and pathological assessments.

Authors:  Joana Reis; Jonas Christoffer Lindstrøm; Joao Boavida; Kjell-Inge Gjesdal; Daehoon Park; Nazli Bahrami; Manouchehr Seyedzadeh; Woldegabriel A Melles; Torill Sauer; Jürgen Geisler; Jonn Terje Geitung
Journal:  Breast Cancer Res Treat       Date:  2020-08-12       Impact factor: 4.624

4.  Correlation between MRI morphological response patterns and histopathological tumor regression after neoadjuvant endocrine therapy in locally advanced breast cancer: a randomized phase II trial.

Authors:  Joana Reis; Owen Thomas; Maryam Lahooti; Marianne Lyngra; Hossein Schandiz; Joao Boavida; Kjell-Inge Gjesdal; Torill Sauer; Jürgen Geisler; Jonn Terje Geitung
Journal:  Breast Cancer Res Treat       Date:  2021-08-06       Impact factor: 4.872
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.